Patents Assigned to Gilead Sciences, Inc.
  • FXR (NR1H4) Modulating Compounds
    Publication number: 20190308962
    Abstract: The present disclosure relates generally to compounds (I) which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: June 9, 2017
    Publication date: October 10, 2019
    Applicant: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • ANTIBODIES AND FRAGMENTS THEREOF THAT BIND HEPATITIS B VIRUS PROTEIN X
    Publication number: 20190309052
    Abstract: Provided herein are, inter alia, antibodies, antigen-binding antibody fragments, cells, polynucleotides, compositions, kits, and methods relating to the detection of HBV protein X (HBx), e.g., in vitro and in vivo. Included are antibodies and fragments thereof that bind HBx, as well as kits, cells, and compositions comprising such antibodies and fragments.
    Type: Application
    Filed: April 1, 2019
    Publication date: October 10, 2019
    Applicant: Gilead Sciences, Inc.
    Inventors: Simon Paul Fletcher, Christian Alfons Voitenleitner
  • FXR (NR1H4) modulating compounds
    Patent number: 10421730
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: September 24, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Process methods for phosphatidylinositol 3-kinase inhibitors
    Patent number: 10414737
    Abstract: A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: September 17, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Stacy Bremner, Jerry B. Evarts, Keiko Sujino, Duong Tran, Dragos Vizitiu
  • Crystalline forms of darunavir
    Patent number: 10407438
    Abstract: The present invention relates to novel crystalline forms of darunavir, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: September 10, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Chiajen Lai, Bing Shi
  • Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
    Patent number: 10385067
    Abstract: The present invention relates to sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I, pharmaceutical formulations, and uses thereof for treating or prophylactically preventing an HIV infection.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: August 20, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Ernest A. Carra, Irene Chen, Vahid Zia
  • COT MODULATORS AND METHODS OF USE THEREOF
    Publication number: 20190248807
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Application
    Filed: April 23, 2019
    Publication date: August 15, 2019
    Applicant: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Gayatri Balan, Chienhung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary B. Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel
  • Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
    Patent number: 10377761
    Abstract: Provided herein are formulations, methods and substituted tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: August 13, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael O'Neil Hanrahan Clarke, Edward Doerffler, Richard L. Mackman, Dustin Siegel
  • Inhibitors of bruton'S tyrosine kinase
    Patent number: 10370381
    Abstract: Provided are forms of 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one, compositions thereof, methods for their preparation, and methods for their use.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: August 6, 2019
    Assignee: Gilead Sciences, Inc.
    Inventor: Bing Shi
  • Toll like receptor modulator compounds
    Patent number: 10370342
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: August 6, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • Compounds for the treatment of HIV
    Patent number: 10370358
    Abstract: The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: August 6, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Steven S. Bondy, Carina E. Cannizzaro, Chien-Hung Chou, Randall L. Halcomb, Yunfeng Eric Hu, John O. Link, Qi Liu, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • HIV PROTEASE INHIBITORS
    Publication number: 20190210978
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herin. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Application
    Filed: October 12, 2018
    Publication date: July 11, 2019
    Applicant: Gilead Sciences, Inc.
    Inventors: Zhenhong R. Cai, Aesop Cho, Ana Zurisadai Gonzalez Buenrostro, Xiaochun Han, Salman Y. Jabri, Ryan McFadden, Yingmei Qi, Johannes Voigt, Hong Yang, Jie Xu, Lianhong Xu
  • HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES
    Publication number: 20190211083
    Abstract: The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.
    Type: Application
    Filed: February 12, 2019
    Publication date: July 11, 2019
    Applicant: Gilead Sciences, Inc.
    Inventors: Mini Balakrishnan, Brian A. Carr, John Corbin, Craig S. Pace, Nathan D. Thomsen, Xue Zhang
  • Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
    Patent number: 10342794
    Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: July 9, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Seung H. Lee, Jennifer R. Lo, Scott A. Mitchell, Aaron C. Schmitt, Sundaramoorthi Swaminathan, Jin-Ming Xiong, Jianjun Xu, Zhongdong Zhao
  • Pyrrolo[1,2-b]pyridazine derivatives
    Patent number: 10336762
    Abstract: Provided is a compound of Formula (I) wherein the variable groups are defined herein.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: July 2, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, John O. Link, James G. Taylor, Winston C. Tse, Nathan E. Wright, Zheng-Yu Yang, Jennifer R. Zhang, Sheila M. Zipfel
  • Substituted pyrrolizine compounds and uses thereof
    Patent number: 10328053
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 25, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • FXR (NR1H4) modulating compounds
    Patent number: 10329286
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: June 25, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Julie Farand, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Tank-binding kinase inhibitor compounds
    Patent number: 10316049
    Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: June 11, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhimin Du, David Dornan, Juan A. Guerrero, Joshua A. Kaplan, John E. Knox, Devan Naduthambi, Barton W. Phillips, Susanna Y. Stinson, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 10314844
    Abstract: Inhibitors for Bruton's Tyrosine Kinase (BTK) are disclosed as are compositions thereof, methods for their preparation, and methods for their use.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: June 11, 2019
    Assignees: GILEAD SCIENCES, INC., ONO PHARMACEUTICAL CO., LTD.
    Inventors: Seung H. Lee, Shingo Yamamoto
  • COT modulators and methods of use thereof
    Patent number: 10316017
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: June 11, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Elizabeth M. Bacon, Gayatri Balan, Chien-Hung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel